Makoff R&D Laboratories

Makoff R&D Laboratories is an Israeli biotechnology research firm that specialized in the development of oral delivery platforms for large molecule drugs. The company's core innovation is the Protein Oral Delivery (POD) technology, which utilizes a unique combination of protease inhibitors and absorption enhancers to protect proteins from degradation in the gastrointestinal tract. In 2006, the company's intellectual property and research assets were acquired by Oramed Pharmaceuticals. This technology has since served as the foundation for Oramed's clinical pipeline, including oral formulations of insulin and GLP-1 analogs for the treatment of diabetes.